Home The Word Brain My Amedeo FAQ Privacy About   


Chinese Coaching

Already know some Chinese? Stay on track with structured, one-on-one coaching to make steady, long-term progress. By Meng Wu and BSK.


  Liver Diseases

  Free Subscription


Articles published in Semin Liver Dis

Retrieve available abstracts of 78 articles:
HTML format



Single Articles


    December 2025
  1. ANTON A, Friedman SL, Cogliati B
    Hepatic fibrosis and liver cancer.
    Semin Liver Dis. 2025 Dec 30. doi: 10.1055/a-2779-4937.
    PubMed     Abstract available


  2. BLANEY H, Horhat A, Saleem A, Winder GS, et al
    Integrated Alcohol Use Disorder and Liver Disease Management.
    Semin Liver Dis. 2025;45:517-530.
    PubMed     Abstract available


  3. WANG TJ, Singh A
    Endohepatology in the Management of Liver Diseases.
    Semin Liver Dis. 2025;45:439-450.
    PubMed     Abstract available


  4. GANGULY S, Sakane S, Hokutan K, Zhang V, et al
    Aging and Aging-Related Senescence in Liver.
    Semin Liver Dis. 2025;45:549-566.
    PubMed     Abstract available


  5. SHALABY S, Ramirez-Quesada WE, Ojeda A, Perez-Campuzano V, et al
    Portosinusoidal Vascular Disorder: When to Suspect and How to Manage?
    Semin Liver Dis. 2025;45:487-497.
    PubMed     Abstract available


    October 2025
  6. XU S, Calderaro J
    Combined hepatocellular-cholangiocarcinoma: a clinical and molecular review.
    Semin Liver Dis. 2025 Oct 24. doi: 10.1055/a-2730-9074.
    PubMed     Abstract available


    September 2025
  7. ISRAELSEN M, Trepo E, Krag A, Stender S, et al
    MetALD: Genetic Factors and Clinical Outcomes.
    Semin Liver Dis. 2025;45:269-282.
    PubMed     Abstract available


  8. WANG R, Ma F, Yin D, Wang H, et al
    Intestinal Microbes, Metabolites, and Hormones in Alcohol-Associated Liver Disease.
    Semin Liver Dis. 2025;45:283-302.
    PubMed     Abstract available


  9. MRAVEC B, Szantova M
    Liver Neurobiology: Regulation of Liver Functions by the Nervous System.
    Semin Liver Dis. 2025;45:420-437.
    PubMed     Abstract available


  10. CAO P, Jaeschke H, Ni HM, Ding WX, et al
    The Ways to Die: Cell Death in Liver Pathophysiology.
    Semin Liver Dis. 2025;45:397-419.
    PubMed     Abstract available


    August 2025
  11. BALOGUN O, Nejak-Bowen K
    Animal Models of Porphyria with Hepatic Involvement.
    Semin Liver Dis. 2025 Aug 21. doi: 10.1055/a-2677-6806.
    PubMed     Abstract available


  12. HASSAN A, Tapper E
    Patient-centered treatment of cirrhosis.
    Semin Liver Dis. 2025 Aug 18. doi: 10.1055/a-2684-6289.
    PubMed     Abstract available


    June 2025
  13. BEIER JI, Luo J, Vanderpuye CM, Brizendine P, et al
    Environmental Pollutants, Occupational Exposures, and Liver Disease.
    Semin Liver Dis. 2025;45:148-166.
    PubMed     Abstract available


  14. GRATACOS-GINES J, Alvarado-Tapias E, Marti-Aguado D, Lopez-Pelayo H, et al
    Diagnosis and Management of Early Stages of ALD.
    Semin Liver Dis. 2025;45:195-209.
    PubMed     Abstract available


  15. WASHINGTON AM, Kostallari E
    Extracellular Vesicles and Micro-RNAs in Liver Disease.
    Semin Liver Dis. 2025;45:167-179.
    PubMed     Abstract available


  16. MARINO Z, Schilsky ML
    Wilson Disease: Novel Diagnostic and Therapeutic Approaches.
    Semin Liver Dis. 2025;45:221-235.
    PubMed     Abstract available


  17. BARBERA A, White TM, Arora AK, Henry L, et al
    Patient-Reported Outcomes in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2025;45:210-220.
    PubMed     Abstract available


  18. TORRES S, Hardesty J, Barrios M, Garcia-Ruiz C, et al
    Mitochondria and Alcohol-Associated Liver Disease: Pathogenic Role and Target for Therapy.
    Semin Liver Dis. 2025;45:180-194.
    PubMed     Abstract available


  19. SINGAL AK
    Preface (Introduction): Metabolic Liver Disease: A New Era in Hepatology.
    Semin Liver Dis. 2025;45:145-147.
    PubMed    


    May 2025
  20. HUANG HYR, Schneider KM, Schneider C
    Big Data Analytics in Large Cohorts: Opportunities and Challenges for Research in Hepatology.
    Semin Liver Dis. 2025 May 21. doi: 10.1055/a-2599-3728.
    PubMed     Abstract available


    April 2025
  21. JIAO H, Wang H, Li J, Yang Z, et al
    The Molecular Pathogenesis of Sarcopenia/Frailty in Cirrhosis.
    Semin Liver Dis. 2025 Apr 16. doi: 10.1055/a-2564-7551.
    PubMed     Abstract available


  22. RAMIREZ-QUESADA W, Alvarado-Tapias E, Shalaby S, Hernandez-Gea V, et al
    Recompensation in Cirrhosis: Biomarkers and Strategies.
    Semin Liver Dis. 2025 Apr 3. doi: 10.1055/a-2542-9930.
    PubMed     Abstract available


  23. SONG Y, Yang X, Yu C
    Understanding and Treating Hepatorenal Syndrome: Insights from Recent Research.
    Semin Liver Dis. 2025 Apr 1. doi: 10.1055/a-2570-3330.
    PubMed     Abstract available


    March 2025
  24. PANT K, Peixoto E, Gradilone SA
    Primary Cilia in Hepatic Biliary Hyperplasia: Implications for Liver Diseases.
    Semin Liver Dis. 2025 Mar 21. doi: 10.1055/a-2563-9791.
    PubMed     Abstract available


  25. SEREROLS-VINAS L, Garcia-Vicien G, Ruiz-Blazquez P, Lee T, et al
    Hepatic stellate cells functional heterogeneity in liver cancer.
    Semin Liver Dis. 2025 Mar 5. doi: 10.1055/a-2551-0724.
    PubMed     Abstract available


  26. LIU T, Zhang F, Feng Y, Han P, et al
    Alcohol-Metabolizing Enzymes, Liver Diseases and Cancer.
    Semin Liver Dis. 2025;45:99-113.
    PubMed     Abstract available


  27. HILSCHER MB, Johnson JN
    Fontan-Associated Liver Disease.
    Semin Liver Dis. 2025;45:114-128.
    PubMed     Abstract available


  28. POHL J, Aretakis D, Tacke F, Engelmann C, et al
    Role of Intestinal Barrier Disruption to Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2025;45:52-65.
    PubMed     Abstract available


  29. ABI-AAD SJ, Lovell M, Khalaf RT, Sokol RJ, et al
    Pathogenesis and Management of Intestinal Failure-Associated Liver Disease.
    Semin Liver Dis. 2025;45:66-80.
    PubMed     Abstract available


  30. ZHANG JW, Zhang N, Lyu Y, Zhang XF, et al
    Influence of Sex in the Development of Liver Diseases.
    Semin Liver Dis. 2025;45:15-32.
    PubMed     Abstract available


  31. WU Q, Yang D, Liu C, Xu T, et al
    Alcohol Plus Additional Risk Factors: Rodent Model of Liver Injury.
    Semin Liver Dis. 2025;45:81-98.
    PubMed     Abstract available


  32. ANWAR AA, Jalan-Sakrikar N, Huebert RC
    LncRNAs, RNA Therapeutics, and Emerging Technologies in Liver Pathobiology.
    Semin Liver Dis. 2025;45:1-14.
    PubMed     Abstract available


    January 2025
  33. PREMKUMAR M, Kajal K, Gupta P, Reddy R, et al
    Current Concepts in Fluid Resuscitation and Vasopressor Use in Cirrhosis.
    Semin Liver Dis. 2025 Jan 14. doi: 10.1055/a-2515-2783.
    PubMed     Abstract available


    November 2024
  34. HUDSON D, Valentin Cortez FJ, Hurtado Diaz de Leon I, Malhi G, et al
    Advancements in MELD score and its impact in Hepatology.
    Semin Liver Dis. 2024 Nov 8. doi: 10.1055/a-2464-9543.
    PubMed     Abstract available


  35. PRADO LG, Nagy LE
    Role of Complement in Liver Diseases.
    Semin Liver Dis. 2024;44:510-522.
    PubMed     Abstract available


  36. POMPILI E, Iannone G, Carrello D, Zaccherini G, et al
    Managing Multiorgan Failure in Acute on Chronic Liver Failure.
    Semin Liver Dis. 2024;44:492-509.
    PubMed     Abstract available


  37. SETHI N, Khokhar M, Mathur M, Batra Y, et al
    Therapeutic Potential of Nutraceuticals against Drug-Induced Liver Injury.
    Semin Liver Dis. 2024;44:430-456.
    PubMed     Abstract available


  38. MAHER S, Rajapakse J, El-Omar E, Zekry A, et al
    Role of the Gut Microbiome in Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:457-473.
    PubMed     Abstract available


  39. DE JONG YP
    Mice Engrafted with Human Liver Cells.
    Semin Liver Dis. 2024;44:405-415.
    PubMed     Abstract available


    October 2024
  40. MEENA BL, Sarin SK
    Management of Portal vein Thrombosis in Cirrhosis.
    Semin Liver Dis. 2024 Oct 4. doi: 10.1055/s-0044-1791247.
    PubMed     Abstract available


    August 2024
  41. ARTEEL GE
    Extracellular matrix and hepatic wound healing before fibrosis.
    Semin Liver Dis. 2024 Aug 27. doi: 10.1055/a-2404-7973.
    PubMed     Abstract available


  42. BALLESTER MP, Durmazer EN, Qi T, Jalan R, et al
    The value of ammonia as a biomarker in patients with cirrhosis.
    Semin Liver Dis. 2024 Aug 2. doi: 10.1055/a-2378-8942.
    PubMed     Abstract available


  43. ZHANG IW, Lurje I, Lurje G, Knosalla C, et al
    Combined Organ Transplantation in Patients with Advanced Liver Disease.
    Semin Liver Dis. 2024;44:369-382.
    PubMed     Abstract available


  44. CHOI YJ, Kim Y, Hwang S
    Role of Neutrophils in the Development of Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:300-318.
    PubMed     Abstract available


  45. THAKRAL N, Desalegn H, Diaz LA, Cabrera D, et al
    A Precision Medicine Guided Approach to the Utilization of Biomarkers in MASLD.
    Semin Liver Dis. 2024;44:273-286.
    PubMed     Abstract available


  46. CHEN C, Feng D, Wang Y, Yao T, et al
    Necrotic Liver Lesion Resolution: Another Mode of Liver Regeneration.
    Semin Liver Dis. 2024;44:333-342.
    PubMed     Abstract available


  47. KOTULKAR M, Paine-Cabrera D, Apte U
    Role of Hepatocyte Nuclear Factor 4 Alpha in Liver Cancer.
    Semin Liver Dis. 2024;44:383-393.
    PubMed     Abstract available


  48. QIAN S, Wang X, Chen Y, Zai Q, et al
    Inflammation in Steatotic Liver Diseases: Pathogenesis and Therapeutic Targets.
    Semin Liver Dis. 2024;44:319-332.
    PubMed     Abstract available


    July 2024
  49. TINCOPA MA, Loomba R
    Noninvasive Tests to Assess Fibrosis and Disease Severity in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic-Dysfunction-Associated Steatohepatitis.
    Semin Liver Dis. 2024 Jul 9. doi: 10.1055/s-0044-1788277.
    PubMed     Abstract available


    May 2024
  50. BALOGUN O, Nejak-Bowen K
    Understanding Hepatic Porphyrias: Symptoms, Treatments, and Unmet Needs.
    Semin Liver Dis. 2024 May 17. doi: 10.1055/s-0044-1787076.
    PubMed     Abstract available


  51. MA J, Bjornsson ES, Chalasani N
    Hepatotoxicity of Antibiotics and Antifungals and Their Safe Use in Hepatic Impairment.
    Semin Liver Dis. 2024 May 13. doi: 10.1055/s-0044-1787062.
    PubMed     Abstract available


  52. WERNER W, Kuzminskaya M, Lurje I, Tacke F, et al
    Overcoming Resistance to Immune Checkpoint Blockade in Liver Cancer with Combination Therapy: Stronger Together?
    Semin Liver Dis. 2024;44:159-179.
    PubMed     Abstract available


  53. FISCHER AM, Lechea N, Coxson HO
    This Is What Metabolic Dysfunction-Associated Steatotic Liver Disease Looks Like: Potential of a Multiparametric MRI Protocol.
    Semin Liver Dis. 2024;44:226-238.
    PubMed     Abstract available


  54. LI CC, Liu M, Lee HP, Wu W, et al
    Heterogeneity in Liver Cancer Immune Microenvironment: Emerging Single-Cell and Spatial Perspectives.
    Semin Liver Dis. 2024;44:133-146.
    PubMed     Abstract available


  55. PHAM N, Benhammou JN
    Statins in Chronic Liver Disease: Review of the Literature and Future Role.
    Semin Liver Dis. 2024;44:191-208.
    PubMed     Abstract available


  56. FUJIWARA N, Kimura G, Nakagawa H
    Emerging Roles of Spatial Transcriptomics in Liver Research.
    Semin Liver Dis. 2024;44:115-132.
    PubMed     Abstract available


    April 2024
  57. SAVIANO A, Roehlen N, Baumert TF
    Tight Junction Proteins as Therapeutic Targets to Treat Liver Fibrosis and Hepatocellular Carcinoma.
    Semin Liver Dis. 2024 Apr 22. doi: 10.1055/s-0044-1785646.
    PubMed     Abstract available


    March 2024
  58. KODAMA T, Takehara T
    Molecular genealogy of metabolic-associated hepatocellular carcinoma.
    Semin Liver Dis. 2024 Mar 18. doi: 10.1055/a-2289-2298.
    PubMed     Abstract available


    February 2024
  59. ROMERO-GOMEZ M, Arab JP, Oliveira CP, Hernandez M, et al
    Is There a Safe Alcohol Consumption Limit for the General Population and in Patients with Liver Disease?
    Semin Liver Dis. 2024;44:69-78.
    PubMed     Abstract available


  60. CANIVET CM, Boursier J, Loomba R
    New Nomenclature for Nonalcoholic Fatty Liver Disease: Understanding Metabolic Dysfunction-Associated Steatotic Liver Disease, Metabolic Dysfunction- and Alcohol-Associated Liver Disease, and Their Implications in Clinical Practice.
    Semin Liver Dis. 2024;44:35-42.
    PubMed     Abstract available


  61. MOUZAKI M, Woo JG, Divanovic S
    Gestational and Developmental Contributors of Pediatric MASLD.
    Semin Liver Dis. 2024;44:43-53.
    PubMed     Abstract available


  62. TUTUSAUS A, Morales A, Garcia de Frutos P, Mari M, et al
    GAS6/TAM Axis as Therapeutic Target in Liver Diseases.
    Semin Liver Dis. 2024;44:99-114.
    PubMed     Abstract available


  63. BESSONE F, Hillotte GL, Ahumada N, Jaureguizahar F, et al
    UDCA for Drug-Induced Liver Disease: Clinical and Pathophysiological Basis.
    Semin Liver Dis. 2024;44:1-22.
    PubMed     Abstract available


  64. EL-KASSAS M, Awad A, Elbadry M, Arab JP, et al
    Tailored Model of Care for Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease.
    Semin Liver Dis. 2024;44:54-68.
    PubMed     Abstract available


  65. BECH KT, Lindvig KP, Thiele M, Castera L, et al
    Algorithms for Early Detection of Silent Liver Fibrosis in the Primary Care Setting.
    Semin Liver Dis. 2024;44:23-34.
    PubMed     Abstract available


  66. LIU H, Sethi V, Li X, Xiao Y, et al
    Corrigendum: Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024;44:e1-e3.
    PubMed    


    January 2024
  67. LIU H, Sethi V, Li X, Xiao Y, et al
    Liver Transplantation for Hepatocellular Carcinoma: A Narrative Review and A Glimpse into The Future.
    Semin Liver Dis. 2024 Jan 11. doi: 10.1055/a-2242-7543.
    PubMed     Abstract available


    November 2023
  68. BALOGUN O, Nejak-Bowen K
    The Hepatic Porphyrias: Revealing the Complexities of a Rare Disease.
    Semin Liver Dis. 2023 Nov 16. doi: 10.1055/s-0043-1776760.
    PubMed     Abstract available


  69. WILSON SR, Duncan AW
    The Ploidy State as a Determinant of Hepatocyte Proliferation.
    Semin Liver Dis. 2023 Nov 15. doi: 10.1055/a-2211-2144.
    PubMed     Abstract available


  70. HAN X, Sun Q, Xu M, Zhu G, et al
    Unraveling the Complexities of Immune Checkpoint Inhibitors in Hepatocellular Carcinoma.
    Semin Liver Dis. 2023 Nov 6. doi: 10.1055/s-0043-1776127.
    PubMed     Abstract available


  71. SAEIDINEJAD M, Elshabrawi A, Sriphoosanaphan S, Andreola F, et al
    Novel Therapeutic Approaches in Treatment of Acute-on-Chronic Liver Failure.
    Semin Liver Dis. 2023;43:429-445.
    PubMed     Abstract available


  72. DUTTA RK, Jun J, Du K, Diehl AM, et al
    Hedgehog Signaling: Implications in Liver Pathophysiology.
    Semin Liver Dis. 2023;43:418-428.
    PubMed     Abstract available


    August 2023
  73. PEKARSKA K, Parker R
    Alcohol-Related Liver Disease: Is There a Safe Alcohol Consumption Limit for Liver Disease?
    Semin Liver Dis. 2023;43:305-310.
    PubMed     Abstract available


  74. RANJBARIAN T, Schnabl B
    Gut Microbiome-Centered Therapies for Alcohol-Associated Liver Disease.
    Semin Liver Dis. 2023;43:311-322.
    PubMed     Abstract available


  75. DESHMUKH K, Apte U
    The Role of Endoplasmic Reticulum Stress Response in Liver Regeneration.
    Semin Liver Dis. 2023;43:279-292.
    PubMed     Abstract available


  76. MEADOWS V, Yang Z, Basaly V, Guo GL, et al
    FXR Friend-ChIPs in the Enterohepatic System.
    Semin Liver Dis. 2023;43:267-278.
    PubMed     Abstract available


  77. COOPER SA, Kostallari E, Shah VH
    Angiocrine Signaling in Sinusoidal Health and Disease.
    Semin Liver Dis. 2023;43:245-257.
    PubMed     Abstract available


  78. RUIZ M, Lacaille F, Schrader C, Pons M, et al
    Pediatric and Adult Liver Disease in Alpha-1 Antitrypsin Deficiency.
    Semin Liver Dis. 2023;43:258-266.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Liver Diseases is free of charge.